PR

Public Relations

Press Release

Hugel Presents Data from Phase 3 Clinical Trial at 2022 American Society of Dermatologic Surgery Annual Meeting
2022-10-11

Hugel Presents Data from Phase 3 Clinical Trial at 2022 American Society of Dermatologic Surgery Annual Meeting

- Result demonstrates that Letybo significantly improved the negative psychological burden associated with glabellar lines

 

Hugel, a global total medical aesthetics company (CEO: Ji-hoon Sohn), announced on 11th that it presented data from its phase 3 clinical trial, BLESS III, of its botulinum toxin, Letybo at the American Society for Dermatologic Surgery (ASDS) taking place in Colorado, from October 6-10, 2022. 

 

BLESS III was a prospective, randomized, double-blind, placebo controlled, multicenter phase 3 clinical trial (N=355) evaluating the efficacy and safety of Letybo in the treatment of glabellar lines. 

Data results that Hugel presented at ASDS highlighted the improvement of the psychosocial health-related quality of life (QoL) of subjects with moderate to severe glabellar lines. 

 

Hyperfunctional glabellar frown lines can transmit facial miscues that adversely affect emotional communication and facial attractiveness, increase perceptions of age, and diminish self-esteem. The BLESS III study included a comprehensive assessment of Letybo’s efficacy on this important aspect of glabellar lines using multiple measures of psychologic impact. Change from baseline to Week 4 in psychological impact was measured by the validated Modified Skindex-16 Glabellar Lines QoL Scale, the FACE-Q Appraisal of Lines Between Eyebrows Scale, and the FACE-Q Age Appraisal Visual Analog Scale (VAS). 

 

According to the study, 89% of patients were satisfied with the outcome from Letybo and they were happy with looking 2.3 years younger after the treatment. Particularly, Letybo significantly improved the negative psychological burden associated with glabellar lines. The validated Modified Skindex-16 Glabellar Lines QoL Scale includes the emotional or the social functioning subscale. In the case of a group injecting Letybo, the overall scores decreased by 38.4, showing a significant difference compared to the placebo group, which decreased by 0.7. FACE-Q score was also found to be significantly higher in Letybo group (46.4) than in the placebo group (-2.9), indicating that psychological changes occurred depending on the degree of improvement in the glabellar line.

 

Jim Hartman, President and COO commented, “We look forward to sharing our analysis of the efficacy of Letybo in mitigating the negative psychological burden associated with glabellar lines and its promotion of subject satisfaction with treatment outcome. Hugel will continue its various medical marketing activities to promote the superior quality, efficacy, and safety of Letybo to the global market.”


Prev Hugel Achieves Record-high Quarterly Sales
Next Hugel Participates in IMCAS ASIA 2022, Holding an Exclusive Academic Symposium